Kirkland, Skadden Lead Eli Lilly's $1.4B Point Biopharma Buy
Kirkland & Ellis LLP-led Eli Lilly and Co. said Tuesday it has agreed to acquire Point Biopharma Global Inc., a developer of targeted cancer therapies, for $1.4 billion, a development that...To view the full article, register now.
Already a subscriber? Click here to view full article